Home > About Us > 2018 Year in Review

Public Policy Advocacy

TCA recognizes the importance of educating lawmakers, policymakers, and other stakeholders of the need and urgency to expand access to evidence-based comprehensive addiction and co-occurring treatment that is based on the full continuum of care.  Throughout 2018, TCA continued to solidify its role as a respected and knowledgeable resource on treatment and SUD policy on Capitol Hill. Over the past year, TCA has had significant successes in advancing its policy priorities as it engaged the Executive Branch and Congress on behalf of its member programs and their clients and others in need of treatment.

TCA continued to keep the spotlight on the need for access to treatment, including by advocating for and achieving historic Congressional action on the Medicaid IMD Exclusion, expanding opportunities for family-based treatment, as well as for sufficient funding of the Substance Abuse Prevention and Treatment (SAPT) Block Grant.


Protecting and Advancing Policy Interests

In 2018, TCA was able to make substantial progress on its key goals of reforming the Medicaid IMD Exclusion and expanding federal funding to expand access to SUD treatment.  Congress and the Administration refocused on the opioid epidemic which resulted in a genuine opportunity for TCA and its agenda, especially as it relates to reforming the Medicaid IMD Exclusion.


Trump Administration

  • In February, TCA reviewed the SUD treatment and opioid related provisions in the Trump Administration FY19 Budget.
  • In early March, TCA reported on the White House Opioid Summit led by Kellyanne Conway. Numerous Cabinet Secretaries discussed SUD treatment and prevention initiatives as well as law enforcement efforts to combat the opioid epidemic.  President Trump concluded with comments on tougher penalties for drug companies and drug dealers.
  • In March, TCA reported on announcement of President Donald J. Trump’s Initiative to Stop Opioids Abuse and Reduce Drug Supply and Demand. Major themes included:
    • Reducing supplies of illicit drugs.
    • Reducing demand and over-prescription of opioids.
    • Increasing access to addiction treatment and recovery supports to include MATand changing the IMD Exclusion.
  • TCA kept members apprised of key personnel developments throughout the year related to the opioid epidemic. On March 29, HHS Secretary Alex Azar announced the appointment of Brett Giroir, M.D. as Senior Advisor to the Secretary for Mental Health and Opioid Policy. Dr. Giroir is responsible for coordinating HHS’s efforts across the Administration to fight America’s opioid crisis.  At the same time, ONDCP continued to function as a secondary entity which operated without permanent leadership for almost the entire 115th Jim Carroll, a former deputy White House chief of staff, was designated as acting drug czar since February 2018 and only was confirmed in the waning hours of the 115thCongress on January 3, 2019.
  • In June, TCA reported on the CMS release of guidance on “Leveraging Medicaid Technology to Address the Opioid Crisis” resulting from the Commission’s recommendations on telemedicine and prescription monitoring as useful tools in the effort to combat the opioid crisis.
  • Late in the year, the Trump Administration announced an initiative to allow Mental Health IMD Waivers as mandated by Section 12003 of the 21st Century Cures Act (Cures Act).” As part of the SMI/SED Demonstration Opportunity, States could receive FFP for services furnished to Medicaid beneficiaries during short term stays for acute care in psychiatric hospitals or residential treatment settings that qualify as IMDs if those states are also taking action, through these demonstrations, to ensure good quality of care in IMDs and to improve access to community-based services as described below.  States may participate in the SUD demonstration opportunity and this SMI/SED demonstration opportunity at the same time.


Throughout 2018, TCA engaged Members their staffs, proactively contacting them in advance of the hearings with suggested questions that would shine a spotlight on the importance and effectiveness of community-based residential treatment and the need to reform or repeal the IMD Exclusion as it relates to inpatient, nonhospital residential SUD treatment.  Passing additional federal legislation to build on CARA before the November 2018 elections became a bipartisan priority for the House and Senate, and TCA advocated aggressively to advance preferred policy proposals in the House and Senate throughout the year, culminating in the passage of H.R. 6, The SUPPORT Act, through the House and Senate and its enactment into law on October 24, 2018.

IMD Exclusion Legislation

  • TCA continued to advance legislation for repeal of the Medicaid IMD Exclusion as it relates to SUD treatment, working closely with Members of the House and Senate to advance a long-term, meaningful solution.
    • SUD-treatment specific legislation carried over from 2017 included the TCA endorsed H.R. 2938, the Road to Recovery Act, introduced by Rep. Brian Fitzpatrick (R-PA), to repeal the IMD Exclusion as it applies to residential, nonhospital inpatient SUD treatment.
    • TCA also continued to engage extensively with Senator Dick Durbin (D-IL) and his staff regarding his bill S. 1169, the Medicaid CARE Act, and its House companion bill, H.R. 2687 sponsored by Rep. Bill Foster (D-IL). 1169/H.R. 2687 would expand access to SUD treatment by modifying the existing Medicaid IMD Exclusion to allow payments for certain residential treatment facilities to treat individuals with substance use disorders and to provide extended duration of residential treatment to pregnant women.
  • On June 11, TCA alerted Members to a Center for Budget and Policy Priorities (CBPP) white paper on the House passed Opioid legislative package arguing against elimination of IMD Exclusion and instead endorsing waivers entitled: Assessing the House Opioid Package’s Medicaid Bills: While Some Advance Access to Treatment, One Raises Serious Concerns.TCA spent considerable effort engaging professional and personal committee staff in the House and Senate to refute assertions made by the CBPP in its white paper, especially to the extent that it unnecessarily and inappropriately characterized efforts to reform the IMD Exclusion as anathema to providing outpatient SUD treatment under Medicaid.

Highlights of this advocacy included the following:

House of Representatives:

  • In February, March, and April, the House Energy and Commerce Committee conducted a series of hearings in preparation for the consideration of major legislation designed to examine and assess current efforts and inform action moving forward. Throughout the process TCA maintained an active presence on the Hill to contribute to and monitor the ongoing debate and resulting legislative drafts and provided TCA with reviews of all hearings and markups.
  • In late April, TCA provided a review of over 50 bills proposed for markup in the Energy and Commerce Health Subcommittee related to combating the opioid crisis, including a bill on the IMD Exclusion which would allow 30-90 days of relief from the IMD Exclusion.TCA monitored the extensive markup and provided updates in real-time.
  • In May TCA monitored and reported on the Energy and Commerce full Committee markup of 34 bills related to combating the opioid crisis, including:
  • Debate and passage of R. 5797 – The IMD Care Act.  The legislation was considerably more limited than the bill approved in the Health Subcommittee a few weeks prior. It was constructed with the same ill-defined five year waiver language but now covers only 30 days for OUD only.
  • TCA also closely tracked one of the most contentious parts of the markup involving Rep. Markwayne Mullin’s (R-OK) legislation to reform 42 CFR Part 2 regarding how medical information for people with SUD is shared.
  • In addition, TCA reported to its members on the markups of legislation in other Committees, including the Judiciary, Ways and Means, Education and Workforce, and Oversight and Government Reform Committees which addressed aspects of the federal response to the opioid epidemic within their jurisdiction. This included reauthorization of the Office of National Drug Control Policy.
  • In June, the full House of Representatives considered a group of over 40 bills, including debate, amendments, and final passage. Designated H.R. 5797, the legislation passed the House by a vote of 261-155 on June 20, 2018.  Beyond H.R. 5797, TCA reported on the action on the other bills that made up the opioid package (H.R. 6) which occurred over the course of two weeks before final passage on June 22, 2018.



During the spring and summer, the Senate also held an extensive series of hearings and markups on the opioid crisis spanning the jurisdiction of six committees.  Highlights of the actions taken and TCA’s advocacy are as follows:

  • In February, TCA submitted comments on Opioid Policy to Senate Finance Committee including recommendations related to addressing the opioid epidemic as the committee reviewed and assessed policy options to determine appropriate policy change within the jurisdiction of the committee.
  • In April, TCA reported on the Senate Health, Education, Labor and Pensions Committee markup of S. 2680, the Opioid Crisis Response Act of 2018, which was favorably reported by a vote of 23-0.Of note was the rejection of an amendment by Sen. Murphy (D-CT) which sought to give USDOL new authority to enforce SUD/MH parity laws as recommended by the Opioid Commission’s recommendation and previously endorsed by USDOL Secretary Acosta.However, during debate on the amendment, Chairman Alexander said that Sec. Acosta had changed his mind, and the amendment failed on a party line vote.
  • In May, TCA reported on the Senate Finance Committee’s release of over 20 bills as part of the federal response to the opioid epidemic which broadly related to changes in the Medicare, Medicaid, and child welfare programs. This package was referred to as the HEAL Substance Use Disorders Act of 2018.
  • In June, TCA worked closely with Senators Portman and Durbin on an IMD Exclusion-related amendment that involved 4 years of Medicaid reimbursed services and required MAT. TCA was in close contact with Sen. Portman’s staff in advance of the markup to discuss many aspects of the amendment.  However, Sen. Portman refrained from offering the amendment in committee markup due to concerns about its cost.
  • Throughout the summer TCA worked very closely with a bipartisan group of Senators: Portman (R-OH), Durbin (D-IL), Brown (D-OH), and Cardin (D-MD) to advance the IMD Exclusion amendment as part of the larger Senate opioid package. During this time, TCA President Kathy Icenhower conducted a call with the opioids package analyst from the Congressional Budget Office on state licensing requirements for IMD Exclusion in an effort to help address concerns about how to pay for proposed policy changes.
  • In September, the Senate passed its version of H.R. 6 – combining the Finance Committee package with legislation passed in the HELP and Judiciary Committees – with placeholder IMD Exclusion language and privacy provisions that differed significantly from the House bill.
  • As a short but intensive period of conference negotiations took place, TCA advocated forcefully for the Senate provisions as preferred in comparison to the House-passed provisions of the IMD Care Act.In approximately a week, House and Senate negotiators agreed on a final legislative package, known as the SUPPORT Act, to address the opioid crisis.
    • As part of the final package, the conference report included Sec. 5052 provisions that would give approximately $900 million in relief from the IMD Exclusion by providing a State with the option to provide Medicaid coverage for certain individuals with substance use disorders who are patients in certain institutions for mental diseases.
    • Also included was the Building Capacity for Family-Focused Residential Treatment Act (S. 2923, Grassley/Menendez), which authorizes $20 million in funding for HHS to award grants to states to develop, enhance, or evaluate family-focused treatment programs to increase the number of evidence-based programs that will later qualify for funding under the FFPSA.
  • Further, the legislation included the Improving Recovery and Reunifying Families Act (S. 2926, Menendez/Scott), which provides a $15 million mandatory appropriation in FY 2019 under Promoting Safe and Stable Families for HHS to conduct an evaluation of a family recovery and reunification replication project.

42 CFR Part 2 SUD Treatment Privacy Provisions

  • Because of the controversial nature of 42 CFR Part 2 reform, H.R. 6082 by Rep. Mullin (R-OK) was not included in the broader opioid package when it was crafted in the House of Representatives. Instead, it was considered by the House as a standalone bill on June 20, 2018.  After debate, the bill passed by a vote of 357 – 57, in which a significant bloc of House Democrats supported the measure, although it was opposed by Energy and Commerce Committee Ranking Member Frank Pallone (D-NJ).
  • In July, TCA sent letters to Senate Leadership: Leader McConnell, Leader Schumer, HELP Chairman Alexander, HELP Ranking Member Murray, Finance Chairman Hatch, and Finance Ranking Member Wyden regarding TCA’s strong opposition to H.R. 6082, the Overdose Prevention and Patient Safety Act. This bill would eliminate an SUD patient’s current legal right and ability to consent to disclose their treatment information for “treatment, payment, and health care operations.” TCA also conducted outreach on the House side to express reservations about H.R. 6082 and its inclusion in any compromise opioid package.
  • Ultimately, H.R. 6082 was not included in the final opioid legislation signed into law.

Despite the Senate setting aside any policy reform for 42 CFR Part 2 in its package,advocates for changes to 42 CFR Part 2 did mount an effort to pass the legislation during the lame duck session of Congress, whether as part of a CR or other legislative measure that was considered “must-pass” before the end of the 115thCongress.

Families First Prevention Services Act –Policy Implementation

  • In February, TCA FY19 Report Language for FFPSA and SUD Coverage

Draft report language to submitted to Congressman Tim Ryan’s (D-OH) office for inclusion in the FY19 Labor, Health and Human Services, and Labor Appropriations bill regarding implementation of the Family First Prevention Service Act.

The Committee is aware that PL-115-123 authorized child welfare funding under Title VII to be used by states to prevent at-risk children from entering the foster care system by permitting a child to live with a parent while they get family-based residential treatment for Substance Use Disorder (SUD).  The Committee understands the goal of this funding is to enable the parent to continue or resume parenting and reduce the burden on the foster care system; therefore the Committee urges the Administration for Children and Families to work with states to ensure that this authority and funding is used to broaden access to family-based SUD treatment.

  • In July,TCA responded to the HHS RFI regarding the Family First Prevention Services Act (FFPSA) entitled: Decisions Related to the Development of a Clearinghouse of Evidence-Based Practices in Accordance With the FFPSA of 2018.
  • Also in July, TCA monitored and reported out on the Ways and Means Subcommittee on Human Resources hearing yesterday on The Opioid Crisis and Implementation of the Family First Prevention Services Act (FFPSA).  As follow up, TCA submitted Questions for the Record to Congresswoman Judy Chu (D-CA) to send along to the witnessJerry Milner, Associate Commissioner, Children’s Bureau Acting Commissioner, ACYF, and HHS.
  • In September, TCA met with Laura Berntsen of the Senate Finance Committee regarding ongoing issues with FFPSA guidance and implementation of pertinent sections of the Opioid package.
  • The final FY19 Labor, Health and Human Services, and Labor Appropriations bill included TCA supported language directing the Administration for Children and Families on FFPSA funds:
    • Kinship Navigator Programs. The conferees continue $20,000,000 in temporary bridge funding for kinship navigator programs in fiscal year 2019 because the Department has not yet identified which evidence-based programs are eligible for funding or issued other guidance to States about how to claim the IV-E matching funds for this purpose. The conferees expect HHS to identify eligible approaches and issue guidance in time for States to use IV-E funds for kinship programs.
    • Regional Partnership Grants. The conferees include $20,000,000 for Regional Partnership Grants to improve the coordination of services for children and families affected by opioid and other substance use disorders. The conferees strongly encourage ACF to prioritize applicants who will focus on preparing programs to qualify as evidence-based foster care prevention services under the Family First Prevention Services Act (P.L. 115-123), to include family-focused residential treatment programs, which help families remain together safely while parents receive treatment.

 Other Congressional Issues

  • Deceptive advertising targeting SUD treatment patients. On July 25, TCA monitored and reported on the House Energy and Commerce Health Subcommittee hearing entitled: “Examining Advertising and Marketing Practices within the Substance Use Treatment Industry.” Following the December 2017 hearing on patient brokering, Members received testimony about other questionable marketing and advertising practices that are largely unregulated at the federal level.  The witnesses expressed openness, in fact a need for, to federal regulation of not only these marketing practices, but also national consistent quality of care standards.
    • In response to the hearing, onAugust 8, Facebook announced plans to restrict addiction treatment advertisements for addiction treatment centers today, amid concerns about shoddy facilities that advertise to patients.

 TCA Advocacy in Washington

TCA Spring Board Meeting and Day on the Hill (June 18-20, 2018)

  • As part of the annual TCA Hill Day, WSW scheduled meetings for all TCA attendees in Washington. TCA members met with 42 offices, including 11 with Members of Congress or Senators, to discuss the value and efficacy of residential treatment, policy priorities including elimination of the Medicaid IMD Exclusion and expanding access to treatment, CMS 1115 waivers, support for increased funding of the SAMHSA Substance Abuse Prevention and Treatment Block Grant, and 42 CFR Part 2 patient privacy policy.
  • TCA conducted a congressional briefing entitled, “1115 SUD Waiver Experience: The Good, the Bad and the Unexpected.” TCA worked to coordinate panel speakers – Robert Kent, General Counsel, New York State Office of Alcoholism and Substance Abuse Services (OASAS), Jen Katzman, Chief of Staff to the Medicaid Director, Louisiana Department of Health Bureau of Health Services Financing, Adam Cohen, Executive Director, Odyssey House-UT, and Dr. Sushma Taylor, CEO, Center Point- and to secure sponsorship of the briefing by the House Addition, Treatment and Recovery Caucus and the Bipartisan Heroin Task Force.  The briefing was well attended with over 40 attendees from 20 congressional offices and professional staff on the Senate Finance Committee, 7 agency staff, and numerous policy and advocacy organizations.

Fall Board Meeting (October 3, 2018)

  • TCA also organized a second day on the Hill opportunity for TCA members with a focus on outreach to Members of Congress and Senators well-positioned to work on issues related to treatment – including those outside of TCA member districts that serve on the House Energy and Commerce and Ways and Means Committees, and the Senate HELP and Finance Committees.  TCA members met with 24 congressional offices on this Day on the Hill.
  • TCA held a Congressional Reception to honor Rep. Harold (Hal) Rogers (R-KY) with the Charlie Devlin Award for Excellence.


TCA provided real-time monitoring and comprehensive reporting on budget activity related to wrapping up the FY2018 process and kicking off the FY2019 process. TCA also monitored and reported out on relevant markups, hearings, press conferences, and other key events.

Bipartisan Budget Act of 2018

In February, Congress concluded the FY2018 budget process.  Congress passed and the President signed the Bipartisan Budget Act (BBA) of 2018, which raised spending caps for FY18 and FY19 was reached in early February.  The BBA also included the following provisions of interest to TCA, most notably the Family First Prevention Services Act.  Further, the legislation allocated another $3 billion in spending specifically focused on addressing the opioid crisis, triple the $1 million authorized in the 21stCentury Cures Act.

FY2018 Omnibus Appropriations bill

Congress passed and the President signed an Omnibus Appropriations bill, funding programs across the federal government.  WSW reported to TCA on provisions of interest upon release of the massive spending package, including:

  • $1.9 billion (level funding from FY2017) for the Substance Abuse and Mental Health Administration (SAMHSA),Substance Abuse Block Grant
  • $1.7 billion to address opioid and heroin abuse, which is an increase of $1.5 billion above last year. This amount includes $500 million for the state opioid response grants authorized in the 21st Century Cures Act, along with funding for programs authorized in the Comprehensive Addiction and Recovery Act.

FY2019 Appropriations

On February 14, the President released his FY2019 budget request.  TCA reported on provisions of interest, including:

  • $1.9 billion (level funding) for the Substance Abuse and Mental Health Administration (SAMHSA), Substance Abuse Block Grant
  • Unfavorable changes to ONDCP’s grants making function

Later in the year, the House and Senate developed their respective versions of the FY19 Labor, Health and Human Services, and Education Appropriations bills which fund a wide range of programs important to TCA related to SUD treatment.  Fortunately, negotiators were able to reach agreement on a Conference Report on the FY19 Labor, HHS, Education Appropriations legislation that allowed for it to receive full year funding before Congress adjourned for the 2018 elections.  Among the highlights of the package were:

  • $1.9 billion in funding for the SAPT Block Grant represents level funding for this particular program.
  • $1.5 billion for State Targeted Response Grants related to the opioid epidemic, an increase of $500 million over FY18.
  • Inclusion of a $20 million grant program for ACF Regional Partnership Grants to improve the coordination of services for children and families affected by opioid and other substance use disorders, with ACF being encouraged to prioritize applicants who will focus on preparing programs to qualify as evidence-based foster care prevention services under the Family First Prevention Services Act “to include family-focused residential treatment programs.”

Building and Strengthening Key Relationships

TCA continued to build and grow meaningful relationships with Members of Congress, as well as with various relevant congressional entities such as the Bipartisan Task Force on Heroin and the ATR Caucus.

  • As part of our advocacy on the IMD Exclusion this year, several TCA members came to Washington to meet with key House and Senate offices. Meeting targets included a broad array of member offices with an interest in or jurisdiction over the IMD Exclusion.
    • Shields for Families: In February, Dr. Kathy Icenhower met with in five Hill offices to discuss waivers for IMD Exclusion and the Families First Prevention Services Act.
    • Integrity House: In May, Bob Budsock met with five Hill offices to discuss the TC model and Residential Care, IMD Exclusion, waivers, and expanding access to appropriate care.
    • Pathway Society, Inc.: Also in May, Gary Montrezza met with eight Hill offices to discuss the TC model and Residential Care, IMD exclusion, waivers, and expanding access to care.
    • Odyssey House Louisiana: In June, Ed Carlson met with nine Hill offices to discuss the IMD Exclusion.

TCA continued to secure a sustainable organization through development activities, increased member communication and improved financial management:

  • TCA held 3 successful board meetings in 2018 that featured timely, expert speakers in the field of substance use disorder treatment, research and prevention.
    • The Winter Board meeting allowed our members to review and revise our strategic plan, set goals and objectives for 2018, review our financial infrastructure, as well as schedule public policy activities (i.e. briefings, hill days) for the year ahead. Attorney J. Nixon Daniel of Beggs and Lane Law Firm did a presentation titled “The Unreimbursed Costs of the Opioid Crisis” after the presentation Attorney Beggs answered questions and discussed a law suit that is currently pending. TCA members also participated in a site visit to a Westcare facility in Nevada and met with Westcare staff who discussed “Treatment Engagement and Crisis Response Training” issues. While at the facility TCA members got a tour and the opportunity to ask questions of the staff.
    • At the Spring Board Meeting the 2018-2020 Election of Officers took place, the results were: Dr. Kathy Icenhower- President; Edward Carlson 1stVice President; Seep Varma – 2ndVice President, Robert Budsock- Treasurer; Gregg Dockins- Secretary and Tino Hernandez- Past President. A presentation was done by Zachary Laris, Senior Policy Advocate from American Academy of Pediatrics, titled “ Opportunities for Improving Access and Outcomes for Children and Families: Implementation of the Families First Prevention Services Act. That evening TCA held a Membership Appreciation Reception, sponsored by Sterling & Sterling, where we celebrated the retirement of Ron Williams (StayN’Out NY), Kathy Riddle (Outreach-NY) and Tino Hernandez (Samaritan Daytop-NY) and acknowledged all of their work and dedication to the association. At this board meeting members attended a TCA briefing on Capitol Hill.  The briefing was sponsored by the Addiction, Treatment and Recovery Caucus and Heroin Task Force and titled “1115 Waivers: The Good, The Bad, and the Unexpected.  Following the briefing, TCA members participated in the “TCA Capitol Hill Day” where they were able to meet with their legislators and discuss their policy priorities.
    • Our fall board meeting featured a presentation by Gary Tennis, President of the National Alliance of Model State Drug Laws (NAMSDL), titled:  Treatment Ethics: Components and Value of Model State Legislation.  Other featured presenters included, Kendra Chiu, Outreach Director of Grant Development and Special Projects and Robert Morrison of National Association of State Alcohol and Drug Directors (NASADAD) where he discussed the Substance Abuse and Prevention Block Grant (SAPTBG). A presentation by James Taylor IV of Heffernan Insurance also took place. A new committee on Ethics was established and is led by Gale Saler of Newport Academy (MD), chair of the committee.
  • On October 2, 2018 TCA members gathered in the nation’s Capital to celebrate decades of federal advocacy in support of people overcoming addiction as well as to honor Representative Hall Rogers (R-KY) with the Charlie Devlin Award for Excellence for his exemplary work and leadership in the substance use disorder field. The leaders of TCA programs from across the country were joined by Members of Congress to honor decades of federal outreach by the organization, which seeks to support and improve policies and funding that provide access to community-based treatment for Substance Use Disorders (SUD).
  • TCA continued to host the monthly “Public Policy” conference call which takes place on the 3rdTuesday of each month at 4:00 pm (EST) and is open to all members.  The call is led by Rob Zucker of Winning Strategies Washington.  This monthly call allows members to get real time updates on Capitol Hill activities and legislation as well as ask policy questions. Members also receive an update on national office activities by the Executive Director.
  • TCA continued to send out a weekly newsletter to all members each Friday.  The newsletter provides our members with ongoing “Public Policy Updates” that notes activities in Congress, monitors legislation of importance, provides updates and information on federal government activities; provides information on webinars and trainings as well as highlights TCA member activities.
  • TCA updated the website which reflects the direction in which TCA continues to grow and enhance the services under our mission. The website now allows members to pay and register for board meetings, membership dues, and access to all policy papers. TCA also continued to host a Facebook page.
  • TCA continues to partner with federal agencies such as SAMHSA, ACF, NIDA, ONDCP, DOL, DOJ and HUD, to name a few. TCA Executive Director participated in numerous “Stakeholder” meetings and focus groups with our federal partners and the Administration to discuss and promote the continuum of care, funding and research. Pat Clay participated in an Opioid Summit held at the White House where President Trump and his wife, the Surgeon General, a number of Secretaries and leaders from HHS, SAMHSA and ONDCP were present.
  • TCA Executive Director, Pat Clay, continues to participate in a number of Coalitions and working groups to include, The Coalition for Whole Health, Addiction Leadership Group, Re-entry Working Group, Coalition to Stop Opioid Addiction, Mental Health Liaison Group, Facing Addiction, Addiction Policy Forum, National Alliance for Model State Drug Laws, Friends of NIDA and the Justice Roundtable.
  • TCA completed its FY 2017 audit with a clean report which documented TCA’s efforts to improve its systems and practices.
  • TCA continued to offer its members an insurance purchasing program through Sterling and Sterling and Heffernan Insurance which allows TCA National Office to receive royalty income as well as provide our members with a variety of insurance program options.
  • TCA continued to work with HPSI, a vendor service company, and receive royalty income through this partnership.
  • TCA Executive Director, Pat Clay, attended the Rx Drug Abuse & Heroin Summit in April. The Summit is the largest national collaboration of professionals from local, state, and federal agencies, treatment providers, and allied communities impacted by prescription drug abuse and heroin use and is a premiereevent for professionals working to address this public health emergency.
  • In October, TCA Executive Director, Pat Clay attended the World Federation of Therapeutic Communities Conference held in Bangkok Thailand. The conference was attended by several TCA members and featured expert speakers from around the world who are the leaders in Substance Use Disorder field.